<DOC>
	<DOCNO>NCT02475330</DOCNO>
	<brief_summary>This single arm Phase II trial investigate feasibility dietary flaxseed ( FS ) supplementation subject receive definitive chemoradiotherapy non-small cell lung cancer ( NSCLC ) . Subjects ingest FS period approximately 8 9 week course radiation treatment . Study participation surveillance last approximately 6 month . Subject specimen collection include : blood , urine , buccal swab 5 time point .</brief_summary>
	<brief_title>Dietary Flaxseed NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Male female , age 18 old Current diagnosis nonsmall cell lung cancer ( NSCLC ) include patient metastatic disease require definitive thoracic mediastinal radiotherapy concurrent chemotherapy . Able provide write informed consent comply study procedure Total plan radiation dose gross disease 6070 Gy . Current diagnosis disease gastrointestinal system , liver , kidney could result altered metabolism excretion study medication ( history major gastrointestinal tract surgery , gastrectomy , gastrostomy , bowel resection , etc . ) history chronic gastrointestinal disorder ( ulcerative colitis , regional enteritis , gastrointestinal bleeding ) Known hypersensitivity flaxseed metabolite , wheat product Taking take investigational drug within 14 day . Taking take Amifostine Mucomyst ( Nacetylcysteine ) within 14 day Current prior use flaxseed , flaxcontaining product , soybean , soycontaining product Current prior use ( limited prior 14 day ) dietary supplement herbal botanical Prior thoracic and/or mediastinal radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>